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Background: People who sustain spinal cord injuries in low- and middle-income countries are vulnerable to life-
threatening complications after discharge. The aim of this trial is to determine the effect on all-cause mortality of a
sustainable model of community-based care provided over the first 2 years after discharge.
Methods and analysis: The CIVIC trial is a single centre, parallel group trial with concealed and stratified randomisation.
The protocol has been previously published (BMJ Open 2016;6:e010350). This paper provides the accompanying detailed
statistical plan. In total, 410 people with recent spinal cord injury who are wheelchair dependent and about to be
discharged from the Centre for the Rehabilitation of the Paralysed in Bangladesh are randomised to intervention or
control groups. Participants assigned to the intervention group receive a model of community-based care in which a
case manager provides ongoing telephone-based support and visits participants in their homes over a 2-year period.
Participants assigned to the control group receive usual care which may involve a follow-up phone call or a home visit.
The primary outcome is all-cause mortality at 2 years as determined by a blinded assessor (Bangladesh does not have
a death registry). The primary effectiveness analysis will compare Kaplan-Meier survival curves (time from allocation to
death) in the intervention and control groups using the log-rank test (two-tailed α = 0.05). Participants will be censored
at the time they were last known to be alive or at the time of the follow-up assessment. Recruitment finished in March
2018 and the last assessment will be conducted in March 2020.
Discussion: The CIVIC trial will provide unbiased and precise estimates of the effectiveness of a model of community-
based care for people with spinal cord injuries in Bangladesh. The results will have implications for provision of health
services for people with spinal cord injuries and other conditions that cause serious disability in low-income and
middle-income countries.
Trial registration: ANZCTR, ACTRN12615000630516, U1111-1171-1876. Registered on 17 June 2015.
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While it is apparent that spinal cord injuries are common
in low- and middle-income countries, robust incidence data
are scarce [1–4] and robust population-based data on mor-
tality rates following spinal cord injuries in low- and
middle-income countries are not available. A longitudinal
cohort study of a representative sample of 350 people with
spinal cord injury who survived until discharge from a spe-
cialised hospital in Bangladesh found that one in five people
who were wheelchair-dependent at discharge had died
within 2 years [5]. Most died from complications related to
pressure ulcers. The problems of pressure ulcers in low-
and middle-income countries is widely documented [1, 6].
Our research team, which includes health professionals
and health service providers based in Bangladesh, has pro-
posed an inexpensive model of community-based care for
people discharged from hospital with spinal cord injury.
The objective is to increase survival after discharge. The
model of care involves assigning a case manager to each
person with spinal cord injury at the time the person is
discharged from hospital. The case manager telephones
the person each fortnight in the first year following dis-
charge and each month in the second year, and visits the
person in their home three times over the first 2 years. At
each point of contact, the case manager screens for com-
plications and provides the person and their families with
ongoing advice, support, and education. There is a par-
ticular focus on preventing and treating pressure ulcers.
The trial commenced in July 2015 and the last partici-
pant was randomised in March 2018. The trial is due for
completion in March 2020. The protocol for the CIVIC
trial has been published [7]. The purpose of this paper is
to provide the detailed statistical analysis plan and allow
future readers of the trial report to confirm that the trial
has been analysed according to a pre-specified plan. The
study will include a formal cost-effectiveness analysis
and a process analysis [8], but they are not described in
this statistical analysis plan.
Methods/design
Aim
The primary aim of the CIVIC trial is to determine
whether a sustainable community-based model of care re-
duces all-cause mortality 2 years after discharge in people
with spinal cord injury in Bangladesh. Secondary aims are
to determine whether this model of care reduces the bur-
den of complications, reduces the prevalence and severity
of pressure ulcers, reduces depression, enhances quality of
life, independence, and participation, and is cost-effective.
Design
The trial is a two-arm parallel pragmatic randomised trial.
It is investigator-driven. The trial is managed by George
Clinical, India.Setting
The trial is being conducted at the Centre for the Re-
habilitation of the Paralysed in Savar, Bangladesh. This is
a not-for-profit hospital that provides care and rehabili-
tation for people with spinal cord injuries. It admits ap-
proximately 350 people with recent spinal cord injuries
each year making it one of the largest spinal injury units
catering for recently injured people with neurological
loss in Asia and the only specialised centre for spinal
cord injuries in Bangladesh.
Participants
In total, 410 people have been randomised to the CIVIC
trial. Participants are people who, at the time of random-
isation, had been admitted to the Centre for Rehabilita-
tion of The Paralysed with an acute spinal cord injury,
and who were over the age of 16 years and were
wheelchair-dependent. Potential participants were ex-
cluded if walking was their usual mode of ambulation or
they planned to move to another country.
Procedures
The full protocol can be found elsewhere [7]. In brief,
participants were randomised in a 1:1 ratio to an inter-
vention or control group using randomly permuted
blocks. The allocation sequence was stratified by level of
lesion (paraplegia or tetraplegia) using the user-written
ralloc command in Stata [9]. Participants in the inter-
vention group receive fortnightly phone calls from a case
manager in the first year after discharge and monthly
phone calls in the second year. They also receive three
home visits over the 2 years and up to AUD $80 to
spend on necessary items. Participants in the control
group receive standard care only. Standard care may
consist of a phone call or a home visit.
The primary outcome is survival (all-cause mortality)
at 2 years after randomisation determined by a blinded
assessor. Bangladesh does not have a death registry, and
so the date of death is confirmed by interviewing next of
kin or carers at 2 years. Wherever possible, independent
corroboration of the date of death is obtained. There are
a number of secondary outcomes, including burden of
complications, prevalence and severity of pressure ul-
cers, depression, quality of life, independence, and par-
ticipation. Questionnaires are administered in the Bangla
language under the guidance of a blinded assessor.
Data management and data integrity
Data are collected in paper format, transferred to George
Clinical India, and entered into an electronic database
(RedCap). Electronically transcribed data are stored and
managed by the Data Management Division of George
Clinical India. Data are double-entered. Automated
checks are conducted to detect data entry errors. Data
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on the database.Sample size
The sample size of 410 gives a better than 80% probabil-
ity of detecting an increase in survival from 83% to 93%
at 2 years with a two-sided log-rank test, uniform
follow-up time of 2 years, loss to follow-up in both
groups of 15% at 2 years, and α of 0.05.
Allowance has been made in sample size calculations
for a single interim analysis conducted when the first 205
participants have been followed up (i.e. at an information
fraction of 205/410 = 0.5) using the O’Brien-Fleming alpha
spending function.1Stopping rules
A recommendation to terminate the trial early for effect-
iveness will only be made if the Data Monitoring Commit-
tee determines both that there is proof beyond reasonable
doubt that the intervention is clearly indicated (that is, the
net benefit—weighing the health benefits against costs,
risks, and inconveniences—clearly favours intervention)
and that the trial provides sufficiently strong evidence of
benefit that it might reasonably be expected to influence
patient care. A recommendation to terminate the trial early
for safety will only be made if the Data Monitoring Com-
mittee determines there is proof beyond reasonable doubt
that the intervention causes an unacceptable net harm.
The trial will not be terminated on the grounds of futility.
A recommendation to terminate the trial will be in-
formed both by a formal interim statistical analysis and
other considerations, including the pattern of effects across
all effectiveness and safety outcomes. The statistical criter-
ion for termination of the trial is that the confidence inter-
val for a beneficial effect includes only clinically important
beneficial effects, or that the confidence interval includes
only clinically important harmful effects. A statistically sig-
nificant test of the null hypothesis of no effect will not, on
its own, be grounds for termination of the trial. A formal
interim analysis will be conducted by an independent stat-
istician and presented to the Data Monitoring Committee
after outcomes have been obtained from approximately
205 participants. The Steering Committee will not be in-
formed of the results of the unblinded interim analysis un-
less a recommendation is made to terminate the trial.Statistical analysis
The analysis will be conducted by statisticians from the
George Institute using SAS. Efficacy analyses will be in-
dependently replicated by one of the investigators using
Stata. Any discrepancies between the two analyses will
be resolved by consensus.General principles
Analyses will be conducted on an intention-to-treat basis.
Hypothesis tests will be conducted but the interpretation
of the trial findings will consider point estimates of effects
and their confidence intervals. Hypothesis tests will be
two-tailed tests (alpha = 0.05). Confidence intervals and p
values will not be adjusted for multiplicity, but interpret-
ation of secondary outcomes will include consideration of
multiplicity.
Trial profile
The flow of participants through the study will be re-
ported in a CONSORT flow diagram. Reasons for exclu-
sion will be provided.
Description of study sample at baseline
The study sample will be described in detail using data
obtained prior to randomisation. Formal between-group
comparisons will not be made on baseline variables.
Adherence
Data will be obtained on adherence to the trial protocol.
For the primary trial report, adherence will be reported as
the number and duration of calls received or the number
of home visits made and these will be expressed as a pro-
portion of the number of calls or home visits specified in
the protocol. The denominator of this proportion will take
into account that calls and home visits cannot occur after
a participant has died.
Efficacy analysis: primary outcome
Primary analysis
The primary effectiveness analysis will compare time to
death from any cause in the intervention and control
groups. Kaplan-Meier survival curves will be compared
using the log-rank test (two-tailed α = 0.05). Participants
will be censored at the time they were last known to be
alive or at the time of the follow-up assessment (intended
to be 2 years after randomisation), whichever is earlier.
Size of effect
The primary estimates of the size of the effect of the
intervention will not be adjusted for covariates. Effect es-
timates will be expressed as:
 a hazard ratio calculated from a simple Cox model
(containing a term for intervention) with 95%
confidence limits.
 both the difference and ratio of the restricted mean
survival times of the intervention and control
groups at 2 years, with 95% confidence limits.
Restricted mean survival times will be estimated by
numerical integration of the Kaplan-Meier curves up
to 2 years. Confidence intervals will be generated
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leagues [10].
 the difference in risk of all-cause mortality at 2 years,
with 95% confidence limits. The confidence interval
will be bounded by Wald (asymptotic) confidence
limits based on the normal approximation.
If there is any discrepancy between the log rank test
used in the primary analysis and the test of the size of
effect implicit in the confidence intervals for estimates
of the size of the effect, the log rank test will be used as
the primary test of effect.Sensitivity analyses
Additional tests will be conducted using:
 a Cox model adjusted for level of lesion (tetraplegia
or paraplegia).
 a combined test of restricted mean survival times
adjusted for level of lesion (tetraplegia or paraplegia)
[11].
 a test of the difference in all-cause mortality at 2 years
adjusted for level of lesion (tetraplegia or paraplegia)
using log-binomial regression.Missing data handling
For the analysis of time to death missing data will not be
imputed. Instead, participants with an unknown vital
status at 2 years will be censored when they were last
known to be alive. For the comparison of all-cause mor-
tality at 2 years, if more than 5% of participants have an
unknown vital status, a further sensitivity analysis will
examine the treatment effect under all possible out-
comes (dead or alive) for all participants with a missing
data endpoint [12]. Within each treatment arm, if we de-
note as mk (k = 0,1) the number of participants with a
missing outcome, we will run mk + 1 possible scenarios
from the most to the least favourable where:
 Scenario 0: 0 participants died
 Scenario 1: 1 participant died
 Scenario 2: 2 participants died
 …
 Scenario mk: mk participants died
For each of the resulting (m0 + 1) × (m1 + 1) combina-
tions, we will calculate a contingency table and associated
chi-square p value and examine which combinations are
consistent with the non-imputed analysis. This will tell us
how extreme the missing data assumption would need to
be to provide a result that is different to the non-imputed
analysis.Subgroup analyses
A subgroup analysis will examine whether the effect of
intervention is moderated by level of lesion (paraplegia
or tetraplegia) or age (< 30, 30–50, > 50 years). The sub-
group analysis will be conducted on the time to death
outcome using a Cox model with terms for intervention,
level of lesion (or age), and the intervention by level of
lesion (or age) interaction.
Efficacy analysis: secondary outcomes
Between-group comparisons of secondary outcomes will
be conducted using linear models, adjusting only for the
stratification and baseline variables. In these models, the
outcome will be a linear function of intervention and level
of lesion (tetraplegia or paraplegia). For continuous out-
comes, baseline scores will be included in the model to in-
crease statistical precision and statistical power. The effect
of intervention on continuous outcomes will be estimated
as the adjusted mean difference and 95% confidence inter-
val. For binary outcomes, log-binomial regression will be
used. The effect of intervention on binary outcomes will
be estimated as the adjusted ratio of proportions and 95%
confidence interval.
Missing data handling
The efficacy analysis of secondary endpoints will use all
available data. Missing data will not be imputed.
Complier average effects and survivor average effects
If there is substantial non-compliance with the interven-
tion (fewer than 75% of planned phone contacts or home
visits), the complier average causal effect of intervention
on all-cause mortality at 2 years will be estimated. The
number of phone contacts and the number of home visits
with participants in the intervention group will be used to
quantify adherence to the protocol by participants in the
intervention group. It will be assumed that participants in
the control group are unable to access the intervention.
The complier average causal effects will be estimated
using instrumental variable regression [13].
If there is a substantially different survival in the inter-
vention and control groups (greater than 5% absolute dif-
ference in survival at 2 years), a sensitivity analysis will be
conducted to determine the plausible range of survivor
average causal effects on secondary outcomes using the
method described by Chiba and Vanderweele [14].
Safety analysis
The safety analysis will consist of documentation of ser-
ious adverse events, deaths, hospitalisations, and events
resulting in persistent or significant disability. Compre-
hensive safety data will be obtained from participants in
the intervention group over the course of the trial be-
cause the research team will be in regular contact with
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complete safety data will be obtained from participants
in the control group over the course of the trial because
the research team has little or no contact with partici-
pants in the control group until follow-up at 2 years.
The closer monitoring of intervention group participants
over the course of the trial generates a potential ascer-
tainment bias which makes interpretation of these safety
data potentially misleading. For that reason, we will not
conduct formal between-group comparisons of safety
data collected over the course of the trial and we do not
anticipate providing details of this information in theFig. 1 The CONSORT flow chart. CRP Centre for the Rehabilitation of the Pprimary trial report. Instead, the efficacy analyses will be
used to provide insights into safety because the primary
outcome and many of the secondary outcomes reflect
adverse events.
Figures and tables
The final report will include the CONSORT flow chart
(Fig. 1) and five tables (Additional file 1).
Discussion
This paper presents the statistical analysis plan for the
CIVIC trial. By publishing the statistical analysis planaralysed, SCI spinal cord injury
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demonstrate, when the trial report is produced, that the
data were analysed according to a pre-specified plan.
Readers of the trial report will be able to check if the
trial was subject to post-hoc or data-driven analyses.Changes from the register and published study protocols
This detailed statistical plan includes two minor changes
to the statistical analysis procedures described briefly in
the trial register and the published protocol. They are:
1. The register indicates that between-group compari-
sons of binary secondary outcomes will be conducted
using logistic regression, but instead log-binomial re-
gression will be used.
2. The published protocol indicates that multiple
imputation will be used if more than 5% of data are
missing for a particular analysis. Instead, efficacy
analyses will be conducted on all available data
without imputation. An analysis of the sensitivity of
findings to missing data will be conducted using the
all-cause mortality outcome.
This statistical analysis plan supersedes the information
previously provided in the registry and the published
protocol. The registry and the working version of the
protocol will be updated to make them consistent with
this statistical analysis plan.Trial status
Key dates in the conduct of the trial are as follows:
 The trial was registered on 17 June 2015 with the
Australian and New Zealand Clinical Trial Registry
(https://www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=368756).
 The first participant was randomised on 12 July 2015.
 The last participant was randomised on 19 March 2018.
 The first participant finished the trial on 3 August 2017.
 The last participant will finish the trial in March 2020.
 The trial protocol was submitted for publication on
23 October 2015 [7].
 This statistical plan is Version 5, dated 12 April 2018.
 This statistical plan was ratified on 12 April 2018
prior to inspection of the data.Endnotes
1In Stata:landemets, alpha(0.05) method(obf) t(0.5(0.5)1)
matrix LANDEMETS = r(bound_alpha)local OBFalpha =
LANDEMETS[2, 5]stpower logrank 0.834 0.934, power(0.8)
alpha(`OBFalpha’) wdprob(0.15)(Note: the landemets com-
mand is a user-written command.)Additional file
Additional file 1: Shells for the five tables that will be included in the
final report of the trial (do not include data). (DOCX 45 kb)
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